Microbix Biosystems Inc. (MBX.TO)
CAD 0.39
(8.33%)
CAD 0.39
(8.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.73 Million CAD | -201.63% |
| 2022 | 2.69 Million CAD | -44.33% |
| 2021 | 4.83 Million CAD | 1021.96% |
| 2020 | -524.6 Thousand CAD | -147.27% |
| 2019 | 1.1 Million CAD | 249.4% |
| 2018 | -742.8 Thousand CAD | 50.46% |
| 2017 | -1.49 Million CAD | -1110.42% |
| 2016 | 148.4 Thousand CAD | -57.47% |
| 2015 | 348.98 Thousand CAD | -26.63% |
| 2014 | 475.62 Thousand CAD | 182.81% |
| 2013 | 168.17 Thousand CAD | 110.67% |
| 2012 | -1.57 Million CAD | 3.95% |
| 2011 | -1.64 Million CAD | 0.58% |
| 2010 | -1.65 Million CAD | 30.32% |
| 2009 | -2.36 Million CAD | 32.12% |
| 2008 | -3.49 Million CAD | -49.07% |
| 2007 | -2.34 Million CAD | -22.07% |
| 2006 | -1.91 Million CAD | -1370.02% |
| 2005 | 151.01 Thousand CAD | 385.23% |
| 2004 | -52.94 Thousand CAD | 87.58% |
| 2003 | -426.33 Thousand CAD | -500.91% |
| 2002 | 106.34 Thousand CAD | -66.05% |
| 2001 | 313.18 Thousand CAD | 179.56% |
| 2000 | -393.65 Thousand CAD | 91.44% |
| 1999 | -4.6 Million CAD | -130.0% |
| 1998 | -2 Million CAD | -1900.0% |
| 1997 | -100 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 2.56 Million CAD | 15.64% |
| 2024 Q2 | 459.06 Thousand CAD | -82.14% |
| 2024 Q3 | 165.31 Thousand CAD | -63.99% |
| 2023 Q3 | -551.03 Thousand CAD | -336.51% |
| 2023 Q2 | 232.98 Thousand CAD | 121.1% |
| 2023 Q1 | -1.1 Million CAD | -456.61% |
| 2023 FY | -2.73 Million CAD | -201.63% |
| 2023 Q4 | 2.22 Million CAD | 503.29% |
| 2022 Q2 | 936.61 Thousand CAD | -16.49% |
| 2022 Q1 | 1.12 Million CAD | -29.04% |
| 2022 FY | 2.69 Million CAD | -44.33% |
| 2022 Q4 | -198.39 Thousand CAD | -123.82% |
| 2022 Q3 | 832.73 Thousand CAD | -11.09% |
| 2021 Q2 | 1.07 Million CAD | 172.99% |
| 2021 FY | 4.83 Million CAD | 1021.96% |
| 2021 Q3 | 1.78 Million CAD | 66.69% |
| 2021 Q4 | 1.58 Million CAD | -11.67% |
| 2021 Q1 | 393.22 Thousand CAD | 578.89% |
| 2020 Q3 | -440.23 Thousand CAD | -100.99% |
| 2020 Q4 | -82.11 Thousand CAD | 81.35% |
| 2020 FY | -524.6 Thousand CAD | -147.27% |
| 2020 Q1 | -585.26 Thousand CAD | -358.18% |
| 2020 Q2 | -219.03 Thousand CAD | 62.58% |
| 2019 Q1 | -119.29 Thousand CAD | 61.16% |
| 2019 Q2 | 482.03 Thousand CAD | 504.07% |
| 2019 FY | 1.1 Million CAD | 249.4% |
| 2019 Q4 | -127.73 Thousand CAD | 33.23% |
| 2019 Q3 | -191.32 Thousand CAD | -139.69% |
| 2018 Q3 | 958.00 CAD | 100.28% |
| 2018 Q2 | -342.5 Thousand CAD | -263.87% |
| 2018 Q1 | -94.12 Thousand CAD | 89.74% |
| 2018 Q4 | -307.13 Thousand CAD | -32160.13% |
| 2018 FY | -742.8 Thousand CAD | 50.46% |
| 2017 FY | -1.49 Million CAD | -1110.42% |
| 2017 Q1 | -525.4 Thousand CAD | -194.51% |
| 2017 Q4 | -917.67 Thousand CAD | -459.2% |
| 2017 Q3 | -164.1 Thousand CAD | -252.44% |
| 2017 Q2 | 107.64 Thousand CAD | 120.49% |
| 2016 Q4 | 555.93 Thousand CAD | 494.05% |
| 2016 FY | 148.4 Thousand CAD | -57.47% |
| 2016 Q1 | -428.42 Thousand CAD | -1861.09% |
| 2016 Q2 | 161.97 Thousand CAD | 137.81% |
| 2016 Q3 | -141.08 Thousand CAD | -187.1% |
| 2015 Q2 | 86.33 Thousand CAD | -4.66% |
| 2015 Q1 | 90.55 Thousand CAD | 129.89% |
| 2015 Q4 | 24.32 Thousand CAD | -83.54% |
| 2015 Q3 | 147.76 Thousand CAD | 71.16% |
| 2015 FY | 348.98 Thousand CAD | -26.63% |
| 2014 Q3 | 294.56 Thousand CAD | 9.25% |
| 2014 FY | 475.62 Thousand CAD | 182.81% |
| 2014 Q4 | -302.96 Thousand CAD | -202.85% |
| 2014 Q2 | 269.62 Thousand CAD | 25.75% |
| 2014 Q1 | 214.4 Thousand CAD | -71.63% |
| 2013 Q4 | 755.83 Thousand CAD | 359.68% |
| 2013 Q2 | 279.61 Thousand CAD | 161.66% |
| 2013 Q1 | -453.45 Thousand CAD | -188.67% |
| 2013 Q3 | 164.42 Thousand CAD | -41.2% |
| 2013 FY | 168.17 Thousand CAD | 110.67% |
| 2012 FY | -1.57 Million CAD | 3.95% |
| 2012 Q3 | 470.94 Thousand CAD | 235.04% |
| 2012 Q2 | -348.73 Thousand CAD | -28.85% |
| 2012 Q1 | -270.65 Thousand CAD | -8.05% |
| 2012 Q4 | 511.41 Thousand CAD | 8.59% |
| 2011 Q4 | -250.47 Thousand CAD | 49.76% |
| 2011 Q2 | -288.28 Thousand CAD | 42.79% |
| 2011 Q1 | -503.93 Thousand CAD | -292.46% |
| 2011 Q3 | -498.51 Thousand CAD | -72.92% |
| 2011 FY | -1.64 Million CAD | 0.58% |
| 2010 Q2 | -358.52 Thousand CAD | 31.46% |
| 2010 Q4 | 261.83 Thousand CAD | 125.4% |
| 2010 FY | -1.65 Million CAD | 30.32% |
| 2010 Q1 | -523.09 Thousand CAD | 44.01% |
| 2010 Q3 | -1.03 Million CAD | -187.56% |
| 2009 Q3 | -443.11 Thousand CAD | 28.76% |
| 2009 Q2 | -621.98 Thousand CAD | -56.02% |
| 2009 Q1 | -398.64 Thousand CAD | 19.98% |
| 2009 FY | -2.36 Million CAD | 32.12% |
| 2009 Q4 | -934.27 Thousand CAD | -110.84% |
| 2008 Q3 | -879.65 Thousand CAD | 28.89% |
| 2008 Q4 | -498.19 Thousand CAD | 43.36% |
| 2008 Q2 | -1.23 Million CAD | -32.24% |
| 2008 Q1 | -935.37 Thousand CAD | -32.18% |
| 2008 FY | -3.49 Million CAD | -49.07% |
| 2007 Q4 | -707.66 Thousand CAD | 15.46% |
| 2007 Q3 | -837.08 Thousand CAD | -119.36% |
| 2007 Q2 | -381.59 Thousand CAD | 8.02% |
| 2007 Q1 | -414.88 Thousand CAD | 67.0% |
| 2007 FY | -2.34 Million CAD | -22.07% |
| 2006 Q4 | -1.25 Million CAD | -556.84% |
| 2006 Q3 | -191.41 Thousand CAD | 45.4% |
| 2006 Q2 | -350.59 Thousand CAD | -195.56% |
| 2006 FY | -1.91 Million CAD | -1370.02% |
| 2006 Q1 | -118.62 Thousand CAD | -116.45% |
| 2005 Q2 | 115.66 Thousand CAD | 252.74% |
| 2005 FY | 151.01 Thousand CAD | 385.23% |
| 2005 Q1 | 32.79 Thousand CAD | -93.19% |
| 2005 Q4 | -54.8 Thousand CAD | -195.53% |
| 2005 Q3 | 57.36 Thousand CAD | -50.4% |
| 2004 FY | -52.94 Thousand CAD | 87.58% |
| 2004 Q2 | -77.46 Thousand CAD | 55.04% |
| 2004 Q3 | -284.89 Thousand CAD | -267.79% |
| 2004 Q4 | 481.72 Thousand CAD | 269.08% |
| 2004 Q1 | -172.3 Thousand CAD | -52.3% |
| 2003 Q3 | -88.57 Thousand CAD | -37.02% |
| 2003 Q2 | -64.64 Thousand CAD | 59.6% |
| 2003 Q1 | -159.98 Thousand CAD | -211.44% |
| 2003 FY | -426.33 Thousand CAD | -500.91% |
| 2003 Q4 | -113.13 Thousand CAD | -27.73% |
| 2002 Q2 | 47.66 Thousand CAD | 127.31% |
| 2002 Q4 | 143.56 Thousand CAD | 60.13% |
| 2002 Q3 | 89.65 Thousand CAD | 88.09% |
| 2002 FY | 106.34 Thousand CAD | -66.05% |
| 2002 Q1 | -174.54 Thousand CAD | -1344.23% |
| 2001 Q4 | 14.02 Thousand CAD | -82.04% |
| 2001 Q3 | 78.11 Thousand CAD | -34.16% |
| 2001 Q2 | 118.63 Thousand CAD | 11.6% |
| 2001 Q1 | 106.3 Thousand CAD | 1575.6% |
| 2001 FY | 313.18 Thousand CAD | 179.56% |
| 2000 FY | -393.65 Thousand CAD | 91.44% |
| 2000 Q4 | 6344.00 CAD | 106.34% |
| 2000 Q3 | -100 Thousand CAD | 66.67% |
| 2000 Q2 | -300 Thousand CAD | 0.0% |
| 2000 Q1 | - CAD | 100.0% |
| 1999 Q2 | -600 Thousand CAD | -50.0% |
| 1999 Q3 | -200 Thousand CAD | 66.67% |
| 1999 Q1 | -400 Thousand CAD | -500.0% |
| 1999 Q4 | -3.3 Million CAD | -1550.0% |
| 1999 FY | -4.6 Million CAD | -130.0% |
| 1998 Q4 | 100 Thousand CAD | 133.33% |
| 1998 Q3 | -300 Thousand CAD | 72.73% |
| 1998 Q2 | -1.1 Million CAD | -57.14% |
| 1998 FY | -2 Million CAD | -1900.0% |
| 1998 Q1 | -700 Thousand CAD | -133.33% |
| 1997 Q1 | - CAD | 0.0% |
| 1997 Q4 | -300 Thousand CAD | -250.0% |
| 1997 Q3 | 200 Thousand CAD | 0.0% |
| 1997 Q2 | - CAD | 0.0% |
| 1997 FY | -100 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Appili Therapeutics Inc. | -8.05 Million CAD | 66.008% |
| Eupraxia Pharmaceuticals Inc. | -36.89 Million CAD | 92.584% |
| Helix BioPharma Corp. | -9.37 Million CAD | 70.799% |
| Medicenna Therapeutics Corp. | -19.66 Million CAD | 86.083% |
| Satellos Bioscience Inc. | -15.46 Million CAD | 82.303% |
| Oncolytics Biotech Inc. | -33.79 Million CAD | 91.902% |
| Sernova Corp. | -41.13 Million CAD | 93.347% |